NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-118-2023-2-PC-01 VACCINE FOR CATS TO BLOCK TOXOPLASMA OOCYST SHEDDING AND TRANSMISSION PCT PCT PCT/US2024/032292 Pending
NICHD E-184-2021-0-MX-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO MX National Stage MX/a/2024/006735 Pending
NCI E-205-2021-0-KR-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF KR National Stage 10-2024-7018383 Pending
NICHD E-184-2021-0-SG-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO SG National Stage 11202403735R Pending
NIAID E-169-2023-0-PC-01 HIV-1 ENVELOPE TRIPLE TANDEM TRIMERS AND THEIR USE PCT PCT PCT/US2024/031661 Pending
NICHD E-184-2021-0-BR-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO BR National Stage BR112024010771-0 Pending
NIAAA E-190-2021-0-IL-01 Thiol-moeity Containing Cannabinoid Receptor Modulating Compounds IL National Stage 313211 Pending
NCI E-199-2021-0-US-02 COMPOSITIONS FOR INHIBITING DIPEPTIDE REPEAT PROTEIN-RIBOSOMAL RNA INTERACTION AND USES THEREOF US National Stage 18/714,298 Pending
NIDCR E-011-2023-0-PCT-01 COPIPARVOVIRUS GENETIC VECTOR PLATFORM PCT PCT PCT/US2024/031301 Pending
NIAID E-004-2009-2-US-29 VIRUS LIKE PARTICLE COMPOSITIONS AND METHODS OF USE US DIV 18/675,059 Pending
NIAID E-021-2019-0-US-02 CONFORMATIONALLY-STABILIZED RSV PREFUSION F PROTEIN US CON 18/675,033 Pending
NIBIB E-168-2021-2-EP-01 SYSTEMS AND METHODS FOR THREE-DIMENSIONAL STRUCTURED ILLUMINATION MICROSCOPY WITH ISOTROPIC SPATIAL RESOLUTION EP National Stage 22890944.6 Pending
NEI E-116-2023-0-PC-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A PCT PCT PCT/US2024/031101 Pending
NCI E-219-2021-0-US-02 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION US National Stage 18/713,490 Pending
NCI E-040-2022-0-US-01 METHODS FOR TREATING BILE DUCT CANCERS WITH TIVOZANIB US National Stage 18/713,533 Pending
NHLBI E-146-2023-0-EP-01 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF EP ORD 24177638.4 Pending
NIAID E-014-2023-0-PC-01 HUMAN MONOCLONAL ANTIBODIES THAT TARGET THE RH5 COMPLEX OF BLOOD-STAGE PLASMODIUM FALCIPARUM PCT PCT PCT/US2024/030637 Pending
NIAID E-055-2024-0-PC-01 METHODS FOR TREATING LUNG DISEASES AND DISORDERS PCT PCT PCT/US2024/030429 Pending
NCI E-099-2023-1-PC-01 T CELL RECEPTORS (TCRS) GENERATED AS A RESULT OF HPV VACCINE THERAPY AND METHODS OF TREATING PATIENTS WITH SAME PCT PCT PCT/US2024/030357 Pending
NCI E-033-2022-0-EP-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS EP National Stage 22854336.9 Pending
NIAID E-240-2020-0-PC-01 RECOMBINANT MURINE PNEUMONIA VIRUS EXPRESSING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE PROTEIN PCT PCT PCT/US2024/029917 Pending
NCI E-042-2014-0-KR-01 Chimeric Antigen Receptors Targeting CD-19 KR DIV 2024-7016401 Pending
NCI E-205-2021-0-EP-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF EP National Stage 22821820.2 Pending
NCI E-033-2022-0-US-02 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS US National Stage 18/710,726 Pending
NCI E-219-2021-0-EP-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION EP National Stage 22844381.8 Pending
NEI E-077-2018-0-US-02 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS US CON 18/664,615 Pending
NIAID E-241-2014-0-US-03 RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 1 (HPIV1) EXPRESSING A CHIMERIC RSV/HPIV1 F PROTEIN AND USES THEREOF US CON 18/665,309 Pending
NIAID E-238-2020-0-US-03 EXPRESSION OF THE SPIKE S GLYCOPROTEIN OF SARS-COV-2 FROM AVIAN PARAMYXOVIRUS TYPE 3 (APMV3) US National Stage 18/710,343 Pending
NCI E-244-2015-0-US-23 BRACHYURY DELETION MUTANTS, NON-YEAST VECTORS ENCODING BRACHYURY DELETION MUTANTS, AND THEIR USE US DIV 18/664,031 Pending
NCI E-021-2015-0-US-02 ANTI-CD70 CHIMERIC ANTIGEN RECEPTORS US DIV 18/663,557 Pending
NIAAA E-190-2021-0-US-02 Cannabinoid Receptor Modulating Compounds US National Stage 18/709,949 Pending
NCI E-113-2021-0-IN-01 BACTERIOPHAGE LAMBDA-VACCINE SYSTEM IN National Stage 202417037929 Pending
NCI E-198-2018-0-US-02 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF US CON 18/661,979 Pending
NICHD E-200-2021-0-EP-01 USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE EP National Stage 22802481.6 Pending
NCI E-142-2014-0-US-02 ANTIGEN-BINDING PROTEINS TARGETING CD56 AND METHODS OF PRODUCING THEREOF US DIV 18/662,315 Pending
NEI E-058-2018-0-US-09 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) Foe Use In Cell Therapy And Tissue Engineered Products US CON 18/662,788 Pending
NIAID E-081-2013-4-US-27 PREFUSION RSV F PROTEINS AND THEIR USE US DIV 18/662,792 Pending
NIAID E-171-2021-0-US-02 SARS-COV-2 SPIKE FUSED TO HEPATITIS B SURFACE ANTIGEN US National Stage 18/709,441 Pending
NCI E-129-2023-0-PC-01 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF PCT PCT PCT/US2024/028832 Pending
NCI E-205-2021-0-US-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF US National Stage 18/708,747 Pending
NCI E-237-2017-2-MX-03 T CELL RECEPTORS RECOGNIZING MUTATED P53 MX DIV MX/a/2024/005676 Pending
NCI E-237-2017-2-MX-02 T CELL RECEPTORS RECOGNIZING MUTATED P53 MX DIV MX/a/2024/005677 Pending
NCI E-237-2017-2-MX-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 MX DIV MX/a/2024/005678 Pending
NIAID E-081-2013-4-EP-25 Prefusion RSV F Proteins And Their Use EP DIV 24174501.7 Pending
NCI E-205-2021-0-JP-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF JP National Stage 2024-526841 Pending
NIAID E-160-2021-0-EP-01 AUGMENTATION OF INNATE AND ADAPTIVE IMMUNITY BY INHIBITION OF INTERACTION OF LILRBS WITH MHC-1 EP National Stage 22803142.3 Pending
NIBIB E-168-2021-2-US-01 SYSTEMS AND METHODS FOR THREE-DIMENSIONAL STRUCTURED ILLUMINATION
MICROSCOPY WITH ISOTROPIC SPATIAL RESOLUTION IMPROVEMENT OF AXIAL RESOLUTION IN 3D SIM VIA OPTICAL AND COMPUTATIONAL MEANS 		US National Stage 18/707,466 Pending
NIAID E-095-2021-0-US-02 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE US National Stage 18/707,305 Pending
NCI E-042-2014-0-JP-01 Chimeric Antigen Receptors Targeting CD-19 JP DIV 2024-074954 Pending
NCI E-169-2021-0-CN-01 MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE CN National Stage 202280073643.1 Pending